Risk of Erythrocytosis in Transgender Individuals Undergoing Testosterone Therapy: A Systematic Review

July 2024 in “ Minerva Endocrinology ”

Alberto Scala, Andrea Graziani, Fabrizio Vianello, Alberto Ferlin, Andrea Garolla, Gender Incongruence Interdisciplinary Group

testosterone therapy erythrocytosis hemoglobin hematocrit serum testosterone levels

Studysummary In this systematic review, an increase in hemoglobin and hematocrit was associated with testosterone therapy, especially within the first year, and factors like serum testosterone levels and therapy specifics were linked to erythrocytosis development, highlighting the need for further research to guide clinical practice.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on research.unipd.it →

Discuss this study in the Community →

Research cited in this study

3 / 3 results

research Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline

2170 citations , September 2017 in “The Journal of Clinical Endocrinology & Metabolism”

This updated guideline from the Endocrine Society highlights the importance of endocrinologists in providing safe and effective hormone regimens for gender-affirming care, especially for adolescents who have entered puberty.

Cross-Sex Hormone Therapy in Trans Persons Is Safe and Effective at Short-Term Follow-Up: Results from the European Network for the Investigation of Gender Incongruence

research Cross-Sex Hormone Therapy in Trans Persons Is Safe and Effective at Short-Term Follow-Up: Results from the European Network for the Investigation of Gender Incongruence

204 citations , May 2014 in “The Journal of Sexual Medicine”

This study concluded that current cross-sex hormone treatments for trans men and trans women are effective with a low risk of side effects in the short term, though they did observe specific clinical changes.

research Effects of Intramuscular Testosterone Undecanoate on Body Composition and Bone Mineral Density in Female-to-Male Transsexuals

105 citations , June 2010 in “The journal of sexual medicine”

In this study, female-to-male transsexuals treated with long-acting testosterone undecanoate experienced an increase in lean mass but no change in fat mass or bone mineral density over 24 months.